Navigation Links
Anti-cancer drug may treat muscular dystrophy

Recent studies on mice reveal that a drug, being tested as an anticancer agent to treat breast cancer, supports recovery from muscular dystrophy//, a disease that has no cure.

Duchene muscular dystrophy is a disease characterized by progressive weakness and degeneration of the muscles that control movement. According to earlier studies, the functional decline of "dystrophic" muscles can be slowed down by agents that enhance muscle fiber size.

The recent study conducted by Dr. P. L. Puri, from The Burnham Institute in La Jolla, California, and colleagues is published on line yesterday in the journal Nature Medicine. According to this study, the anticancer drug trichostatin A or TSA increases muscles fiber size in two mouse models of muscular dystrophy. Mice with this disability, when given TSA for 3 months, were able to run on treadmills and swim as long as healthy mice. According to the researchers, the drug caused no obvious side effects or signs of toxicity. TSA belongs to a class of drugs called deacetylase inhibitors.

The dystrophic muscles became resistant to contraction-related degeneration when treated with trichostatin A and this is linked with functional and morphological recovery. "We have identified a new rationale for treating muscular dystrophy, aimed at correcting the devastating effects of a single flawed gene," Dr Lorenzo Puri said in a statement. "In the window of time that we have analysed these mice, they seem to perform like normal mice. All the decreases in muscle performance were restored by the treatment. "This is a significant advance over the use of steroid -- currently the only treatment available -- which offers palliative relief, often with severe side effects," he said.

Ms Sharon Hesterlee, a vice-president of the association, which helped finance the research, said "I am hesitant to call the finding a breakthrough, because that could raise expectations unfairly, but it's certainly an i mportant finding."

Puri said, "Extensive investigation is now required to determine if these animal findings also apply to humans with muscular dystrophy. It is difficult to predict how long it will take before these studies will be translated into therapies for human patients," he added. "The next step is to test TSA on larger animals, such as golden retrievers, which contract a form of muscular dystrophy more similar to that in humans, " Dr Puri said.

One in every 3,500 male births is affected by this inherited disease. According to the Muscular Dystrophy Association, 40,000-60,000 people in the US have some form of the inherited disease.
GYT
'"/>




Related medicine news :

1. An Anti-cancer Smart Bomb delivered using a Nanocell
2. Gene Study Offers Hope of Potent Anti-cancer Drugs
3. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
4. Thyroid hormone treatment hastens recovery after cardiac surgery
5. Feeding channel created by malaria parasite - a new target for malaria treatments
6. New drug to treat Heart Attack and damaged tissue
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion ... established an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data ... October 1, 2016. , Sarcopenia is defined as a combination of low muscle mass ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... affected by a health insurance co-operative bankruptcy to receive their prescription medications ... receive over 1,500 FDA-approved prescription medications from over 180 American pharmaceutical companies ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... announced its latest offering, the Protocol Calendar Exchange , is officially open ... pre-built, pre-reviewed protocol calendars available for sites to download into their clinical trial ...
(Date:4/28/2016)... Vail, Colorado (PRWEB) , ... April 28, 2016 ... ... LaPrade, MD, PhD, Chief Medical Officer at the Steadman Philippon Research Institute ... Capitol Hill Day to raise awareness about the debilitating and costly musculoskeletal ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... intelligent business communication applications and infrastructure for telecommunication service providers is pleased ... at Bestel’s Communications Network. The ACONYX Number Portability solution fully meets ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology: